Generex Biotechnology Corporation announced the issuance of a white paper on the use of cannabis for medicinal purposes and the joint venture between Generex and CannScience Innovations Inc. for the design and development of products for the delivery of cannabinoids and cannabinoid-derived formulations into the human body via the buccal mucosa (the inner lining of the mouth).
The white paper is authored by Dr. Lakshmi P. Kotra, B. Pharm. (Hons), Ph.D. and Dr. Angelica M. Bello. Dr. Kotra is the Director at the Center for Molecular Design and Preformulations (CMDP) at University Health Network (UHN) in Toronto, Canada, a scientist and principal investigator at UHN, and an Associate Professor of Medicinal Chemistry at the Leslie Dan Faculty of Pharmacy, University of Toronto. Dr. Bello is a scientific associate at UHN.
The white paper builds upon the recently announced formalization of the Co-Development and Technology Licensing Agreement between Generex and CannScience pursuant to which Generex has licensed its proprietary RapidMistT drug delivery platform technologies to CannScience for product co-development and commercialization.
The white paper highlights the resurgent interest in the pharmacologic activity of active ingredients extracted from cannabis and the application thereof to the adjuvant treatment of a myriad of medical conditions. The paper also notes the consequent global trend toward legalization of the production and distribution of cannabis for medical purposes.
The paper describes the extraction of cannabis concentrates and references the work of CannScience to develop extraction protocols and optimal delivery formulations and the role being played by the Generex RapidMistT drug delivery technologies. The objective of the Generex-CannScience co-development arrangements is to bring together a comprehensive set of proprietary tools to provide efficacious and dose-specific medicinal cannabis in a safe and simple manner to patients as a solution to the problems of dose control, bioavailability, and safety risks associated with smoking and edibles.
The white paper may be viewed online on the Generex website.